|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
CNS/CV Biological Research, Schering-Plough Research Institute, Kenilworth, New Jersey
Vinpocetine is a clinically used synthetic vincamine derivative with a
diverse pharmacological profile that includes action at several ion channels,
principally "generic" populations of sodium channels that give
rise to tetrodotoxin-sensitive conductances. A number of cell types are known
to express tetrodotoxin-resistant (TTXr) sodium conductances, the molecular
bases of which have remained elusive until recently. One such TTXr channel,
termed NaV1.8, is of particular interest because of its prominent
and selective expression in peripheral afferent nerves. The effects of
vinpocetine on TTXr channels specifically, are unknown. We have assessed the
effects of the drug on cloned rat NaV1.8 channels expressed in a
dorsal root ganglion-derived cell line, ND7/23. Vinpocetine produced a
concentration- and state-dependent inhibition of NaV1.8 sodium
channel activity. Voltage-clamp experiments revealed an
3-fold increase
in vinpocetine potency when whole-cell NaV1.8 conductances were
elicited from relatively depolarized potentials (35 mV; IC50
= 3.5 µM) compared with hyperpolarized holding potentials (90 mV;
IC50 = 10.4 µM). Vinpocetine also produced an
22 mV
leftward shift in the voltage dependence of NaV1.8 channel
inactivation but did not affect the voltage range of channel activation. These
properties are reminiscent of several other known sodium channel blockers and
suggested that vinpocetine may exhibit frequency-dependent block. Accordingly,
tonic block of NaV1.8 channels by vinpocetine (3 µM) increased
proportionally with increasing depolarizing commands over the frequency range
0.1 to 1Hz. In summary, the present data demonstrate that vinpocetine is
capable of blocking NaV1.8 sodium channel activity and suggest a
potential additional utility in various sensory abnormalities arising from
abnormal peripheral nerve activity.
Address correspondence to: Dr. Tony Priestley, CNS/CV Biological Research, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. E-mail: tony.priestley{at}spcorp.com
This article has been cited by other articles:
![]() |
L. M. Sharkey, X. Cheng, V. Drews, D. A. Buchner, J. M. Jones, M. J. Justice, S. G. Waxman, S. D. Dib-Hajj, and M. H. Meisler The ataxia3 Mutation in the N-Terminal Cytoplasmic Domain of Sodium Channel Nav1.6 Disrupts Intracellular Trafficking J. Neurosci., March 4, 2009; 29(9): 2733 - 2741. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Seda, F. M Pinto, S. Wray, C. G Cintado, P. Noheda, H. Buschmann, and L. Candenas Functional and Molecular Characterization of Voltage-Gated Sodium Channels in Uteri from Nonpregnant Rats Biol Reprod, November 1, 2007; 77(5): 855 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhao, R. Ziane, A. Chatelier, M. E. O'Leary, and M. Chahine Lidocaine Promotes the Trafficking and Functional Expression of Nav1.8 Sodium Channels in Mammalian Cells J Neurophysiol, July 1, 2007; 98(1): 467 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Medina, T. E. Krahe, and A. S. Ramoa Restoration of Neuronal Plasticity by a Phosphodiesterase Type 1 Inhibitor in a Model of Fetal Alcohol Exposure J. Neurosci., January 18, 2006; 26(3): 1057 - 1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Devaux and S. S. Scherer Altered Ion Channels in an Animal Model of Charcot-Marie-Tooth Disease Type IA J. Neurosci., February 9, 2005; 25(6): 1470 - 1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Wittmack, A. M. Rush, M. J. Craner, M. Goldfarb, S. G. Waxman, and S. D. Dib-Hajj Fibroblast Growth Factor Homologous Factor 2B: Association with Nav1.6 and Selective Colocalization at Nodes of Ranvier of Dorsal Root Axons J. Neurosci., July 28, 2004; 24(30): 6765 - 6775. [Abstract] [Full Text] [PDF] |
||||